Host: Sujatha Reddy, MD

Guest: Beth Plante, MD

Fluid management is an essential component of any successful hysteroscopy and hysteroscopically directed procedure. Find out more about a new fluid management system that’s transforming the user experience—not only for physicians, but for nurses and OR staff as well—with Dr. Sujatha Reddy and Dr. Beth Plante, Reproductive Endocrinology and Infertility Specialist from the Fertility Centers of New England.

Guest: Oluwatosin Goje, MD

Since bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) are recurrent conditions that come back frequently and often without reason, improvement in diagnosis and management would also mean improving these women’s physical, mental, and sexual health. Join Dr. Oluwatosin Goje, Obstetrician Gynecologist from the Cleveland Clinic, to explore how you can use molecular testing to improve your patients’ care.

Host: Jennifer Caudle, DO

Guest: Shawn Dhillon, MD

Guest: Debbie D.

For patients with dyslipidemia experiencing myalgia, sticking to their cholesterol management plan can be a challenge. As healthcare professionals, it’s critical to help address challenges by encouraging patients to discuss any adverse reactions they experience with their statin. By having this frank discussion, HCPs can employ an individualized approach to statin selection that may help address and overcome issues that lead to patient noncompliance with statin therapy, and in turn, help achieve efficacy goals.

Join this discussion as Dr. Jennifer Caudle welcomes Dr. Shawn Dhillon, Medical Director at Calvert Medical Group in Baltimore, and Debbie, a patient with dyslipidemia who experienced statin side effects, to discuss the importance of communication with patients with dyslipidemia experiencing myalgia.

Thanks to rapid advances in genetic testing many cell-free DNA prenatal screening tests are available to you in your patient today. One very important quality metric is called fetal fraction. If fetal fraction is not incorporated in the assessment of a trisomy, then potentially only the maternal portion is analyzed and without the baby, thereby leading to potential false negatives or discordant calls.

Professional societies like ACOG and ACMG have included statements and information on the importance of measuring fetal fraction in a prenatal test. Cell-free DNA prenatal screening was originally conceived and designed to reduce unnecessary invasive testing and anxiety for expecting parents.

The Harmony Prenatal Test was developed by Ariosa Diagnostics, a CLIA-certified laboratory. As with other lab-developed tests, it has not been cleared or approved by the FDA and is not available for sale as an IVD in the US. Non-invasive prenatal testing (NIPT) based on cell-free DNA analysis is not diagnostic; results should be confirmed by diagnostic testing.

Host: Matt Birnholz, MD

Guest: Charlotte A. Gaydos, DrPH, MPH

Misdiagnosis of vaginal infections can lead to inappropriate treatment of vaginal infections, prolong symptoms, and increase an affected woman’s risk of developing serious complications. Clinical procedures and traditional diagnostic techniques are insufficient to accurately diagnose the most common types of vaginal infections.

Dr. Charlotte A. Gaydos, Professor of the Division of Infectious Diseases at Johns Hopkins University in Baltimore, Maryland, joins Dr. Matt Birnholz to discuss a validated in vitro diagnostic molecular solution designed to simplify, standardize, and improve the accuracy of vaginal infection diagnosis.

Host: Matt Birnholz, MD

Guest: Madelaine A. Feldman, MD, FACR

Creating meaningful relationships with your local, state and national legislatures may be easier than you think! As physicians continue to incorporate more services in their offices, they may face local and/or state legislative challenges. Ease this transition by learning more about how to become an advocate and partner with your state and local patient advocacy chapters with host Dr. Matt Birnholz and guest Dr. Mattie Feldman, Clinical Associate Professor of Medicine at Tulane University Medical School and Vice-President of the Coalition of State Rheumatology Organizations.

PP-AU-US-0395, 04/2018 ©Lilly USA, LLC 2018. All rights reserved.

Host: Matt Birnholz, MD

Guest: Madelaine A. Feldman, MD, FACR

Creating meaningful relationships with your local, state and national legislatures may be easier than you think! As physicians continue to incorporate more services in their offices, they may face local and/or state legislative challenges. Ease this transition by learning more about how to become an advocate and partner with your state and local patient advocacy chapters with host Dr. Matt Birnholz and guest Dr. Mattie Feldman, Clinical Associate Professor of Medicine at Tulane University Medical School and Vice-President of the Coalition of State Rheumatology Organizations. PP-AU-US-0395, 04/2018 ©Lilly USA, LLC 2018. All rights reserved.

Guest: Robert Phillips Heine, MD

In 2016, there were more than two million cases of chlamydia, gonorrhea, and syphilis reported in the United States. Women and infants, in particular, are at significant risk for long-term consequences of STDs if left undiagnosed or are untreated resulting in serious health consequences, including infertility, life-threatening ectopic pregnancy, and stillbirth in infants.

Join Dr. Phillip Heine, Professor of Obstetrics & Gynecology and Pediatrics at Duke University Medical Center in Durham, NC, as he discusses the role of the obstetrician and gynecologist can have when diagnosing and testing for STI in this patient population.

Host: John J. Russell, MD

Guest: James Wetmore, MD

Guest: Michael Germain, MD

Guest: Barbara Weis Malone, RN

Guest: Mike Spigler

Secondary hyperparathyroidism (HPT) refers to the excessive secretion of parathyroid hormone (PTH) by the parathyroid glands in response to decreased renal function and impaired mineral metabolism.1,2 Secondary HPT often occurs in advanced chronic kidney disease (CKD) and may be initially silent and asymptomatic.2 As a result, it is frequently underdiagnosed and undertreated.1,3 Management of secondary HPT and advanced CKD requires the coordinated efforts of a multidisciplinary team of healthcare professionals.2 Host Dr. John Russell welcomes a diverse panel, including Dr. James Wetmore, Dr. Michael Germain, registered nurse Barbara Weis Malone and Mike Spigler of the American Kidney Fund®. Tune in as we discuss the unique role each team member plays in the clinical management of secondary HPT, as well as recommended best practices to help synchronize this approach and optimize care for these patients. 1 Joy MS et al. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007; Jun;13(5)397-411. 2 Tomasello S. Secondary Hyperparathyroidism and Chronic Kidney Disease. Diabetes Spectr. 2008; Jan;21(1)19-25. 3 National Kidney Foundation. Parathyroid Hormone and Secondary Hyperparathyroidism in Chronic Kidney Disease. Available at: www.kidney.org/sites/default/files/02-10-4899_GB_SHPT-PTH_v8.pdf. Accessed May 17, 2017. USA-416-062150

Host: Prathima Setty, MD

Guest: Justin M. Brewer, MD

There are numerous options for pregnancy screening, making the decision of what type of genetic testing to offer your patients more complex. On today’s program, Dr. Justin Brewer will discuss the most important factors for healthcare professionals to consider when screening their pregnant patients. The focus is on non-invasive prenatal testing and carrier screening panels. Dr. Justin Brewer is a practicing OB/GYN and Maternal-Fetal Medicine Specialist at North Mississippi Medical Center in Tupelo, Mississippi. Dr. Brewer is a professional member of the American College of Obstetrics and Gynecology, the Society of Maternal-Fetal Medicine, the American Institute for Ultrasound and Medicine and the Mississippi State Medical Association. The Harmony Prenatal Test was developed by Ariosa Diagnostics, a CLIA-certified laboratory. As with other lab-developed tests, it has not been cleared or approved by the FDA and is not available for sale as an IVD in the US. Non-invasive prenatal testing (NIPT) based on cell-free DNA analysis is not diagnostic; results should be confirmed by diagnostic testing.